Preventing Drug-Induced Hyperglycemia Through Risk-Aware Therapy

Abstract

Drug-induced hyperglycemia represents a significant and frequently underestimated complication in various clinical settings, particularly in patients receiving long-term pharmacological therapy for chronic conditions. By understanding the mechanisms, risk factors, and preventive strategies, clinicians can mitigate the risk of hyperglycemia and its associated morbidity. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, diagnostic approaches, management strategies, and guideline recommendations for preventing drug-induced hyperglycemia, emphasizing the importance of risk-aware therapy in optimizing patient outcomes.

Introduction

Drug-induced hyperglycemia occurs when certain medications disrupt glucose homeostasis, leading to elevated blood sugar levels in patients with or without pre-existing glucose intolerance. With the expanding use of pharmaceuticals such as corticosteroids, antipsychotics, immunosuppressants, and some antineoplastic agents, the incidence of drug-induced hyperglycemia is rising. Understanding its multifactorial etiology and implementing risk-aware therapy are essential for healthcare professionals to prevent acute complications and long-term sequelae such as diabetes mellitus and cardiovascular disease.

Epidemiology / Disease Burden

The prevalence of drug-induced hyperglycemia varies depending on the patient population and the medications involved. Corticosteroids, for instance, can induce hyperglycemia in up to 50% of non-diabetic hospitalized patients. Second-generation antipsychotics, particularly olanzapine and clozapine, are associated with a two- to four-fold increased risk of new-onset diabetes. The burden is especially pronounced in vulnerable populations such as the elderly, those with pre-existing metabolic syndrome, and patients undergoing chemotherapy or organ transplantation. The clinical and economic implications are substantial, as drug-induced hyperglycemia increases hospital length of stay, risk of infections, and healthcare costs.

Pathophysiology

The pathogenesis of drug-induced hyperglycemia is multifaceted and highly dependent on the class of medication. Corticosteroids induce insulin resistance by promoting hepatic gluconeogenesis and impairing peripheral glucose uptake. Atypical antipsychotics disrupt insulin signaling and may increase adiposity, further exacerbating insulin resistance. Immunosuppressants such as tacrolimus and cyclosporine impair pancreatic beta-cell function and insulin secretion. Other agents, including certain antivirals, thiazide diuretics, and beta-blockers, contribute through various mechanisms such as altered insulin sensitivity, increased hepatic glucose output, or direct pancreatic toxicity. Genetic predisposition and underlying metabolic dysfunction modulate individual susceptibility.

Risk Factors

Multiple patient- and drug-related risk factors influence the development of drug-induced hyperglycemia. Patient-related risks include obesity, advanced age, family history of diabetes, pre-existing impaired glucose tolerance, and metabolic syndrome. Drug-related factors encompass dose, duration, route of administration, and polypharmacy with other hyperglycemic agents. Notably, high-dose corticosteroid therapy and the use of potent second-generation antipsychotics confer the greatest risk. Concomitant use of other diabetogenic medications further amplifies the likelihood of hyperglycemic events, underscoring the importance of individualized risk assessment prior to therapy initiation.

Clinical Features

Drug-induced hyperglycemia may be asymptomatic or present with the classic symptoms of hyperglycemia, including polyuria, polydipsia, blurred vision, fatigue, and unexplained weight loss. Severe cases can progress to acute complications such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), particularly in susceptible individuals. In hospitalized patients, hyperglycemia is associated with increased risk of infections, delayed wound healing, and higher mortality rates. Chronic, uncontrolled hyperglycemia can accelerate the development of microvascular and macrovascular complications, mirroring those seen in primary diabetes mellitus.

Diagnosis

Diagnosis of drug-induced hyperglycemia is based on standard glucose criteria, including fasting plasma glucose, random blood glucose, and glycated hemoglobin (HbA1c) levels. However, the timing of glucose assessment is crucial, as fluctuations may occur depending on the pharmacokinetics of the offending drug. Continuous glucose monitoring (CGM) and frequent capillary blood glucose checks are recommended in high-risk patients, especially following initiation or dose escalation of hyperglycemic agents. Differential diagnosis should exclude pre-existing diabetes, stress-induced hyperglycemia, and other secondary causes.

Treatment & Management

Management strategies focus on mitigating hyperglycemia while balancing the therapeutic benefits of the causative drug. Dose reduction, temporary discontinuation, or substitution with a less diabetogenic alternative may be considered when feasible. Lifestyle interventions, including dietary modification and increased physical activity, remain foundational. Pharmacologic management often involves the use of insulin, as oral hypoglycemic agents may be inadequate in cases of profound insulin resistance or beta-cell dysfunction. Regular monitoring of glucose is imperative, particularly during periods of increased risk such as corticosteroid pulses or chemotherapy cycles. Interprofessional collaboration among prescribers, endocrinologists, and pharmacists is key to optimizing therapy and minimizing adverse outcomes.

Recent Advances / Emerging Therapies

Emerging research highlights the utility of predictive risk stratification tools and pharmacogenomics in anticipating drug-induced hyperglycemia. Novel agents with lower diabetogenic potential are under development, particularly within the antipsychotic and immunosuppressant classes. Advances in CGM technology facilitate early detection and proactive management of glucose excursions. Additionally, there is growing interest in the use of SGLT2 inhibitors and GLP-1 receptor agonists for mitigating corticosteroid-induced hyperglycemia, although robust clinical trial data are pending. Personalized medicine approaches, integrating genetic, metabolic, and pharmacological profiles, promise to enhance risk-aware therapy in the near future.

Guideline Recommendations

Professional societies, including the American Diabetes Association (ADA) and the Endocrine Society, recommend baseline and periodic glucose monitoring in patients receiving known diabetogenic medications, particularly corticosteroids and antipsychotics. Risk assessment should guide drug selection and dosing, with preference given to agents with favorable metabolic profiles when possible. Early intervention, patient education, and multidisciplinary management are emphasized to minimize the incidence and impact of drug-induced hyperglycemia. Individualized care plans, incorporating shared decision-making and patient preferences, are essential for optimizing long-term outcomes.

Conclusion

Preventing drug-induced hyperglycemia requires a comprehensive, risk-aware approach that integrates an understanding of drug mechanisms, patient risk factors, and evidence-based prevention and management strategies. Through vigilant monitoring, judicious prescribing, and interdisciplinary collaboration, clinicians can significantly reduce the burden of this iatrogenic complication and improve patient safety and quality of care. Ongoing research and innovation in pharmacotherapy and personalized medicine will further enhance the ability to predict, prevent, and manage drug-induced hyperglycemia in diverse patient populations.